Progress of companion diagnostics in chimeric antigen receptor T-cell therapy
10.3760/cma.j.cn115356-20220929-00279
- VernacularTitle:伴随诊断在嵌合抗原受体T细胞治疗中的研究进展
- Author:
Zhongpei HUANG
1
;
Chenggong LI
;
Heng MEI
Author Information
1. 华中科技大学同济医学院附属协和医院血液科，武汉 430022
- Keywords:
Immunotherapy, adoptive;
Hematologic neoplasms;
Chimeric antigen receptor T-cell;
Tumor markers, biological;
Molecular targeted therapy;
Companion diagnost
- From:
Journal of Leukemia & Lymphoma
2023;32(8):501-505
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved good efficacy in treatment of hematological malignancies. As a precise and individualized treatment method, CAR-T is gradually moving towards commercialization. In addition to the introduction of corresponding policies and guiding principles, the related detection protocols should also be updated and improved to maximize its effect and achieve precise individualization. This article introduces and expands the concept of "companion diagnostics" that first appeared in targeted drugs, and introduces the significances of various detection technologies and biomarkers for patient screening, safety monitoring and evaluation of efficacy and CAR-T function in the whole process of CAR-T treatment.
